Clinical and serologic factors associated with lupus pleuritis

Shikha Mittoo, Allan Gelber, Carol A. Hitchon, Earl D. Silverman, Janet E. Pope, Paul R. Fortin, Christian Pineau, C. Douglas Smith, Hector Arbillaga, Dafna D. Gladman, Murray B. Urowitz, Michel Zummer, Ann E. Clarke, Sasha Bernatsky, Marie Hudson, Lori B. Tucker, Ross E. Petty, Glinda S. Cooper, Lori Albert, Gaëlle ChedévilleSarah Campillo, Karen Duffy, Rosie Scuccimarri, Murray Baron, Laeora Berkson, Suzanne Ramsey, Adam Huber, Christine A. Peschken

Research output: Contribution to journalArticle

Abstract

Objective. Pleuritis is a common manifestation and independent predictor of mortality in systemic lupus erythematosus (SLE). We examined the prevalence of pleuritis and factors associated with pleuritis in a multicenter Canadian SLE cohort. Methods. We studied consecutive adults satisfying the American College of Rheumatology (ACR) classification criteria for SLE who had a completed Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) score, at least 1 evaluable extractable nuclear antigen assay, and either a SLE Disease Activity Index (SLEDAI) or a SLE Activity Measure score. Pleuritis was defined as having pleuritis by satisfying the ACR criteria or the SLEDAI. Factors related to pleuritis were examined using univariate and multivariate logistic regression. Results. In our cohort of 876 patients, 91% were women, 65% Caucasian, mean age (±SD) was 46.8 ± 13.5 years, and disease duration at study entry was 12.1 ± 9.9 years; the prevalence of pleuritis was 34% (n = 296). Notably, greater disease duration (p = 0.002), higher SDI score (p ≤ 0.0001), age at SLE diagnosis (p = 0.009), and anti-Sm (p = 0.002) and anti-RNP (p = 0.002) seropositivity were significantly associated with pleuritis. In multivariate analysis with adjustment for disease duration, age at diagnosis, and SDI score, concomitant seropositivity for RNP and Sm were related to a nearly 2-fold greater prevalence of pleuritis (OR 1.98, 95% CI 1.31-.82). Conclusion. Pleuritis occurred in one-third of this Canadian cohort. Concomitant Sm and RNP seropositivity, greater cumulative damage, longer disease duration, and younger age at SLE disease onset were related to a higher rate of SLE pleural disease. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)747-753
Number of pages7
JournalJournal of Rheumatology
Volume37
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Pleurisy
Systemic Lupus Erythematosus
Rheumatology
Pleural Diseases
Nuclear Antigens
Multivariate Analysis
Logistic Models

Keywords

  • Antibodies
  • Pulmonary disease
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Mittoo, S., Gelber, A., Hitchon, C. A., Silverman, E. D., Pope, J. E., Fortin, P. R., ... Peschken, C. A. (2010). Clinical and serologic factors associated with lupus pleuritis. Journal of Rheumatology, 37(4), 747-753. https://doi.org/10.3899/jrheum.090249

Clinical and serologic factors associated with lupus pleuritis. / Mittoo, Shikha; Gelber, Allan; Hitchon, Carol A.; Silverman, Earl D.; Pope, Janet E.; Fortin, Paul R.; Pineau, Christian; Smith, C. Douglas; Arbillaga, Hector; Gladman, Dafna D.; Urowitz, Murray B.; Zummer, Michel; Clarke, Ann E.; Bernatsky, Sasha; Hudson, Marie; Tucker, Lori B.; Petty, Ross E.; Cooper, Glinda S.; Albert, Lori; Chedéville, Gaëlle; Campillo, Sarah; Duffy, Karen; Scuccimarri, Rosie; Baron, Murray; Berkson, Laeora; Ramsey, Suzanne; Huber, Adam; Peschken, Christine A.

In: Journal of Rheumatology, Vol. 37, No. 4, 04.2010, p. 747-753.

Research output: Contribution to journalArticle

Mittoo, S, Gelber, A, Hitchon, CA, Silverman, ED, Pope, JE, Fortin, PR, Pineau, C, Smith, CD, Arbillaga, H, Gladman, DD, Urowitz, MB, Zummer, M, Clarke, AE, Bernatsky, S, Hudson, M, Tucker, LB, Petty, RE, Cooper, GS, Albert, L, Chedéville, G, Campillo, S, Duffy, K, Scuccimarri, R, Baron, M, Berkson, L, Ramsey, S, Huber, A & Peschken, CA 2010, 'Clinical and serologic factors associated with lupus pleuritis', Journal of Rheumatology, vol. 37, no. 4, pp. 747-753. https://doi.org/10.3899/jrheum.090249
Mittoo S, Gelber A, Hitchon CA, Silverman ED, Pope JE, Fortin PR et al. Clinical and serologic factors associated with lupus pleuritis. Journal of Rheumatology. 2010 Apr;37(4):747-753. https://doi.org/10.3899/jrheum.090249
Mittoo, Shikha ; Gelber, Allan ; Hitchon, Carol A. ; Silverman, Earl D. ; Pope, Janet E. ; Fortin, Paul R. ; Pineau, Christian ; Smith, C. Douglas ; Arbillaga, Hector ; Gladman, Dafna D. ; Urowitz, Murray B. ; Zummer, Michel ; Clarke, Ann E. ; Bernatsky, Sasha ; Hudson, Marie ; Tucker, Lori B. ; Petty, Ross E. ; Cooper, Glinda S. ; Albert, Lori ; Chedéville, Gaëlle ; Campillo, Sarah ; Duffy, Karen ; Scuccimarri, Rosie ; Baron, Murray ; Berkson, Laeora ; Ramsey, Suzanne ; Huber, Adam ; Peschken, Christine A. / Clinical and serologic factors associated with lupus pleuritis. In: Journal of Rheumatology. 2010 ; Vol. 37, No. 4. pp. 747-753.
@article{d6bbd00304574cd2a5fdc432db63f5fb,
title = "Clinical and serologic factors associated with lupus pleuritis",
abstract = "Objective. Pleuritis is a common manifestation and independent predictor of mortality in systemic lupus erythematosus (SLE). We examined the prevalence of pleuritis and factors associated with pleuritis in a multicenter Canadian SLE cohort. Methods. We studied consecutive adults satisfying the American College of Rheumatology (ACR) classification criteria for SLE who had a completed Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) score, at least 1 evaluable extractable nuclear antigen assay, and either a SLE Disease Activity Index (SLEDAI) or a SLE Activity Measure score. Pleuritis was defined as having pleuritis by satisfying the ACR criteria or the SLEDAI. Factors related to pleuritis were examined using univariate and multivariate logistic regression. Results. In our cohort of 876 patients, 91{\%} were women, 65{\%} Caucasian, mean age (±SD) was 46.8 ± 13.5 years, and disease duration at study entry was 12.1 ± 9.9 years; the prevalence of pleuritis was 34{\%} (n = 296). Notably, greater disease duration (p = 0.002), higher SDI score (p ≤ 0.0001), age at SLE diagnosis (p = 0.009), and anti-Sm (p = 0.002) and anti-RNP (p = 0.002) seropositivity were significantly associated with pleuritis. In multivariate analysis with adjustment for disease duration, age at diagnosis, and SDI score, concomitant seropositivity for RNP and Sm were related to a nearly 2-fold greater prevalence of pleuritis (OR 1.98, 95{\%} CI 1.31-.82). Conclusion. Pleuritis occurred in one-third of this Canadian cohort. Concomitant Sm and RNP seropositivity, greater cumulative damage, longer disease duration, and younger age at SLE disease onset were related to a higher rate of SLE pleural disease. The Journal of Rheumatology",
keywords = "Antibodies, Pulmonary disease, Systemic lupus erythematosus",
author = "Shikha Mittoo and Allan Gelber and Hitchon, {Carol A.} and Silverman, {Earl D.} and Pope, {Janet E.} and Fortin, {Paul R.} and Christian Pineau and Smith, {C. Douglas} and Hector Arbillaga and Gladman, {Dafna D.} and Urowitz, {Murray B.} and Michel Zummer and Clarke, {Ann E.} and Sasha Bernatsky and Marie Hudson and Tucker, {Lori B.} and Petty, {Ross E.} and Cooper, {Glinda S.} and Lori Albert and Ga{\"e}lle Ched{\'e}ville and Sarah Campillo and Karen Duffy and Rosie Scuccimarri and Murray Baron and Laeora Berkson and Suzanne Ramsey and Adam Huber and Peschken, {Christine A.}",
year = "2010",
month = "4",
doi = "10.3899/jrheum.090249",
language = "English (US)",
volume = "37",
pages = "747--753",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - Clinical and serologic factors associated with lupus pleuritis

AU - Mittoo, Shikha

AU - Gelber, Allan

AU - Hitchon, Carol A.

AU - Silverman, Earl D.

AU - Pope, Janet E.

AU - Fortin, Paul R.

AU - Pineau, Christian

AU - Smith, C. Douglas

AU - Arbillaga, Hector

AU - Gladman, Dafna D.

AU - Urowitz, Murray B.

AU - Zummer, Michel

AU - Clarke, Ann E.

AU - Bernatsky, Sasha

AU - Hudson, Marie

AU - Tucker, Lori B.

AU - Petty, Ross E.

AU - Cooper, Glinda S.

AU - Albert, Lori

AU - Chedéville, Gaëlle

AU - Campillo, Sarah

AU - Duffy, Karen

AU - Scuccimarri, Rosie

AU - Baron, Murray

AU - Berkson, Laeora

AU - Ramsey, Suzanne

AU - Huber, Adam

AU - Peschken, Christine A.

PY - 2010/4

Y1 - 2010/4

N2 - Objective. Pleuritis is a common manifestation and independent predictor of mortality in systemic lupus erythematosus (SLE). We examined the prevalence of pleuritis and factors associated with pleuritis in a multicenter Canadian SLE cohort. Methods. We studied consecutive adults satisfying the American College of Rheumatology (ACR) classification criteria for SLE who had a completed Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) score, at least 1 evaluable extractable nuclear antigen assay, and either a SLE Disease Activity Index (SLEDAI) or a SLE Activity Measure score. Pleuritis was defined as having pleuritis by satisfying the ACR criteria or the SLEDAI. Factors related to pleuritis were examined using univariate and multivariate logistic regression. Results. In our cohort of 876 patients, 91% were women, 65% Caucasian, mean age (±SD) was 46.8 ± 13.5 years, and disease duration at study entry was 12.1 ± 9.9 years; the prevalence of pleuritis was 34% (n = 296). Notably, greater disease duration (p = 0.002), higher SDI score (p ≤ 0.0001), age at SLE diagnosis (p = 0.009), and anti-Sm (p = 0.002) and anti-RNP (p = 0.002) seropositivity were significantly associated with pleuritis. In multivariate analysis with adjustment for disease duration, age at diagnosis, and SDI score, concomitant seropositivity for RNP and Sm were related to a nearly 2-fold greater prevalence of pleuritis (OR 1.98, 95% CI 1.31-.82). Conclusion. Pleuritis occurred in one-third of this Canadian cohort. Concomitant Sm and RNP seropositivity, greater cumulative damage, longer disease duration, and younger age at SLE disease onset were related to a higher rate of SLE pleural disease. The Journal of Rheumatology

AB - Objective. Pleuritis is a common manifestation and independent predictor of mortality in systemic lupus erythematosus (SLE). We examined the prevalence of pleuritis and factors associated with pleuritis in a multicenter Canadian SLE cohort. Methods. We studied consecutive adults satisfying the American College of Rheumatology (ACR) classification criteria for SLE who had a completed Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) score, at least 1 evaluable extractable nuclear antigen assay, and either a SLE Disease Activity Index (SLEDAI) or a SLE Activity Measure score. Pleuritis was defined as having pleuritis by satisfying the ACR criteria or the SLEDAI. Factors related to pleuritis were examined using univariate and multivariate logistic regression. Results. In our cohort of 876 patients, 91% were women, 65% Caucasian, mean age (±SD) was 46.8 ± 13.5 years, and disease duration at study entry was 12.1 ± 9.9 years; the prevalence of pleuritis was 34% (n = 296). Notably, greater disease duration (p = 0.002), higher SDI score (p ≤ 0.0001), age at SLE diagnosis (p = 0.009), and anti-Sm (p = 0.002) and anti-RNP (p = 0.002) seropositivity were significantly associated with pleuritis. In multivariate analysis with adjustment for disease duration, age at diagnosis, and SDI score, concomitant seropositivity for RNP and Sm were related to a nearly 2-fold greater prevalence of pleuritis (OR 1.98, 95% CI 1.31-.82). Conclusion. Pleuritis occurred in one-third of this Canadian cohort. Concomitant Sm and RNP seropositivity, greater cumulative damage, longer disease duration, and younger age at SLE disease onset were related to a higher rate of SLE pleural disease. The Journal of Rheumatology

KW - Antibodies

KW - Pulmonary disease

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=77950688279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950688279&partnerID=8YFLogxK

U2 - 10.3899/jrheum.090249

DO - 10.3899/jrheum.090249

M3 - Article

C2 - 20110526

AN - SCOPUS:77950688279

VL - 37

SP - 747

EP - 753

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -